Dr. Ajai Chari, director of clinical research in the Multiple Myeloma Program at The Tisch Cancer Institute and lead author of both studies, explained for Medical News Today how it works: Basically one side is binding to the immune cells known as T cells, and the other side is binding to the myeloma cancer cell, and when those T cells are brought into proximity of the cancer [] they release chemicals that poke holes in the cancer cell membrane and the cancer cells die., Dr. Baker was cautiously optimistic about the therapy: Talquetamab sticks to both cancer-killing immune cells and myeloma cells, helping the immune system to recognize and destroy the cancer. Talquetamab/Daratumumab Shows Promise in Heavily Pretreated Myeloma Taste changes were very common, Aronson said. Talquetamab is a 'first in class' bispecific antibody that targets the GPRC5D, a new target expressed on myeloma cells, and CD3, a protein expressed on T-cells. Oyster mushrooms for cancer: Do they help? Researchers said 5% to 6% of patients stopped talquetamab treatment early due to side effects. Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety. Epcoritamab Shows a Manageable Safety and Robust Antitumour Duration of delay from the last dose administered Action . These cells, made in the bone marrow, are a vital part of . Multiple myeloma is a cancer of plasma cells. Before Topics covered: startup launches, funding, IPOs and much more. If you follow a few myelomagroups on Facebook you might have seen a really gnarly picture of the hands of a patient in a Talquetamab trial. Onco-Nursing Experts Define Best Practices, Treatment Considerations for Managing Patients With MPNs. The fast-advancing pipeline could expand options for multiple myeloma patients, but also raise questions about how treatments should be sequenced and how future drug trials might best be designed. The myeloma cancer cells also build up in the bone marrow and form tumors. Although T cells expressing CD38 might be attacked by AMG 424, this side effect is acceptable because the advantages outweigh the disadvantages . Side Effects: Some Common, Some Unusual. For patients experiencing palmar/plantar desquamation, ammonium lactate lotion, and emollients have shown efficacy. Posted: 12/11/2022 10:00:00 AM Of these, more than 30% had a complete response, meaning that, following treatment, the researchers could detect no myeloma-specific markers. The primary endpoint of the study was met. DREAMM-5 study: investigating the synergetic effects of belantamab mafodotin plus inducible T-cell co-stimulator agonist (aICOS) combination therapy in patients with relapsed/refractory multiple myeloma [abstract]. Side effects with talquetamab were meanwhile relatively frequent, but typically mild. Janssen Submits Biologics License Application to U.S. FDA for No other study participants in the trial had the same genotype. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma. A Study of Talquetamab in Participants With Relapsed or Refractory Many patients who reported burning, glossitis, we would treat for candida because our [ear nose and throat] ENT doctor felt that in the setting of such severe dryness, they may not present with oral plaques. Side effects include: Thrombocytopenia with . Doctors can treat and control the disease, but it is currently regarded as not curable. "With a median follow-up of 14.9 months (range 0.5+ to 29.0), 74.1 percent of patients treated at the SC [subcutaneous] 0.4 mg/kg dose administered weekly achieved a response, 59.4 percent achieved a very good partial response or better, 33.6 percent achieved a complete response or better and 23.8 percent achieved a stringent complete response," reported pharmaceutical company Johnson & Johnson in a press release. More than 7 days . Talquetamab, Cevostamab and Elranatamab in RRMM That data has revealed most patients treated with talquetamab experienced mild side effects, but only around five percent had to cease treatment due to those adverse effects. This year, among the several bi-specifics on the ASH agenda, Talquetamab still peaks my interest. The cases occurred in one adult and one younger study participant. Talquetamab induced a substantial response among patients with heavily pretreated relapsed or refractory multiple myeloma that had progressed with established therapies or who could not receive these therapies without unacceptable side effects. Immune checkpoints are a potential target for MM therapy since they are overexpressed in MM plasma cells . NS-001. Bluebird attributed both to underlying genetics specifically, a condition known as alpha thalassemia trait that is associated with anemia. Talquetamab had moderate side effects. In total, 55.3% of patients experienced dysgeusia, 21.1% experienced dry mouth, and 22.4% experienced dysphagia. Dr. Chari explained: Myeloma response means [] theres a 50% reduction in the myeloma level, so if its less than 50% it is not considered a response and when you submit to the [Food and Drug Administration], and when they look at regulatory approval, its 50% or higher. FDA/EMA Accept Ide-Cel Applications for Earlier R/R Multiple Myeloma Use. Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Martnez-Lpez J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ. Ive been fighting Multiple Myeloma for more than 15 years. Expand Kikuchi T, Tsukada N, Nomura M, Kasuya Y, Oda Y, Sato K, Takei T, Ogura M, Abe Y, Suzuki K, Ishida T. Ann Hematol. No unexpected side effects were seen with this association. A Study of Comparing Talquetamab to Belantamab Mafodotin in The American Society of Hematologys annual conference is the years biggest stage for the most consequential research in treating blood diseases, attracting doctors, drugmakers and investors eager to vet the latest clinical trial results. Talquetamab is a CPRC5DxCD3 . In this instance, talquetamab binds to CD3, a receptor on immune T cells, and GPRC5D, a receptor found in high levels on cancerous plasma cells. Abstract - American Society of Hematology Side effects, CRS, but also I wanted to point out, unique to this target, we also saw nail toxicity, because GRC5D is expressed on keratinized tissue, also dysgeusia, which, which is a little . Anything less doesnt count.. The years biggest meeting on blood diseases kicked off this past weekend. So those are side effects of both bispecific antibodies and CAR-T cells. Data from patients who had received these same dosing regimens in the first phase were included in the analysis for the second phase. Researchers said 5-6% of patients stopped talquetamab treatment early due to side effects. Talquetamab is a bispecific antibody, a type of monoclonal antibody that redirects T cells to act against myeloma cells. Please enable it to take advantage of the complete set of features! FDA Approval Sought for Talquetamab for the Treatment of R/R Multiple Talquetamab is an investigational, off-the-shelf (ready to use), bispecific T-cell engager antibody targeting both GPRC5D, a novel drug target . Side Effects I've Experienced with Talquetamab - myelomablog Track your myeloma and find treatment options, Journal your myeloma story in video, audio and writing, Learn from 150+ myeloma experts in video lessons, Find a free personal coach to help navigate your myeloma, Join our new social media app for myeloma patients, Tackle challenges and crush your fitness goals together, Stay up-to-date with thousands of myeloma news articles, Listen to one-on-one interviews with experts on clinical trials, Attend in-person meetings with myeloma experts, Join community groups with other patients and caregivers, Answer survey questions to advance myeloma research, Find answers to commonly asked questions when navigating HealthTree services. Myeloma Bispecific Antibody Talquetamab Update - HealthTree for Myeloma The researchers state that adverse side effects to talquetamab occurred "relatively frequently" but were most often mild. We have lot of patients start a nail hardener at the onset of therapy.. Ac., CYT, Enzalutamide, combined with standard treatment, shows promise in prostate cancer, What to know about endometrial stromal sarcoma. This is a target that is present on plasma cells and has come up as a newer target that can be exploited for disease control. We are getting into the realm of treatment in myeloma where the newer drugs are sometimes coming up with unique side effects. G protein-coupled receptor, family C, group 5, member D (GPRC5D) is an orphan receptor expressed in malignant plasma cells. Management of Relapsed-Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice. Read on for details and takeaways from the meeting over the weekend: Like many new drug targets, its name is complicated and better off abbreviated. Injection-site reactions were observed in 7.9% of patients. Talquetamab Shows Durable and Continuous Response Treating R/R Multiple Talquetamab, a G protein-coupled receptor family C group 5 member D X CD3 bispecific antibody, in relapsed/refractory multiple myeloma: updated efficacy and safety results from MonumenTAL-1. Just under three-quarters of participants given a lower or higher dose of talquetamab in the Phase 2 portion of J&J's study responded to treatment, with around a third of each group achieving remission of their cancer. Sikander Ailawadhi, MD, discussed the safety and efficacy of talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma following a readout of the phase 1/2 MonumenTAL-1 trial. After initial priming, patients received either weekly or biweekly dosing throughout the study duration.